Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
1.
Vaccine ; 41(50): 7525-7531, 2023 Dec 07.
Artigo em Inglês | MEDLINE | ID: mdl-37973510

RESUMO

Since 1969, rubella and its harmful effect on fetuses infected in utero can be prevented by rubella vaccine, usually given in combination with measles vaccine. The rubella vaccine is highly protective both in children and in adults including women intending to become pregnant. Owing to the use of combined measles and rubella vaccines, congenital rubella infection has been eliminated from the Western Hemisphere and nearly all of Europe. Such combined vaccination is now being applied throughout the world, posing the possibility of eventual rubella eradication. The existence of viruses of animals related to rubella does not appear to be a barrier to eradication of the human virus. However, persistent rubella virus in infants infected in utero and of immunosuppressed patients with granulomas may pose a problem for eradication. Nevertheless, this review posits that eradication of rubella is now feasible if routine vaccination of infants and surveillance for chronic infection are correctly applied.


Assuntos
Sarampo , Rubéola (Sarampo Alemão) , Criança , Lactente , Gravidez , Adulto , Humanos , Feminino , Vacina contra Rubéola/uso terapêutico , Sarampo/epidemiologia , Vacina contra Sarampo , Vírus da Rubéola , Vacinação , Vacina contra Sarampo-Caxumba-Rubéola
2.
Mayo Clin Proc ; 95(8): 1780-1795, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32753151

RESUMO

In addition to the vaccines due in the first year of life, the US Advisory Committee on Immunization Practices recommends that children continue to receive vaccines regularly against a variety of infectious diseases. Starting at 12 to 15 months of life, these include the two-dose measles-mumps-rubella vaccine series and the two-dose varicella vaccine series. Also in the second year of life, infants should begin the two-dose hepatitis A vaccine series and complete the Haemophilus influenzae type B vaccine series as well as the pneumococcal conjugate vaccine series. Before 19 months of life, infants should receive the third dose of the poliovirus vaccine and the fourth dose of diphtheria-tetanus-acellular pertussis (DTaP) vaccine. The final doses of poliovirus and tetanus-diphtheria-acellular pertussis vaccines are both due at 4 to 6 years of life. Before each influenza season, every child should receive the influenza vaccine. Those less than 9 years of age who previously received less than two doses need two doses a month apart. At 11 to 12 years of life, all should get two doses of the human papillomavirus vaccine, the adolescent/adult version of the tetanus-diphtheria-acellular pertussis vaccine, and begin a two-dose series of meningococcal ACWY vaccine. Each of these vaccines is due when the vaccine works to protect against both an immediate risk as well as to provide long-term protection. Each vaccine-preventable disease varies in terms of the nature of exposure, the form of the morbidity, the risk of mortality, and potential to prevent or ameliorate its harm.


Assuntos
Vacinas/uso terapêutico , Adolescente , Fatores Etários , Vacina contra Varicela/normas , Vacina contra Varicela/uso terapêutico , Criança , Pré-Escolar , Vacina contra Difteria, Tétano e Coqueluche/normas , Vacina contra Difteria, Tétano e Coqueluche/uso terapêutico , Feminino , Vacinas contra Hepatite A/normas , Vacinas contra Hepatite A/uso terapêutico , Humanos , Lactente , Vacinas contra Influenza/normas , Vacinas contra Influenza/uso terapêutico , Masculino , Vacina contra Sarampo/normas , Vacina contra Sarampo/uso terapêutico , Vacinas Meningocócicas/normas , Vacinas Meningocócicas/uso terapêutico , Vacina contra Caxumba/normas , Vacina contra Caxumba/uso terapêutico , Vacinas contra Papillomavirus/normas , Vacinas contra Papillomavirus/uso terapêutico , Vacina contra Rubéola/normas , Vacina contra Rubéola/uso terapêutico , Fatores Sexuais , Vacinas/normas
3.
Pediatr Dermatol ; 37(5): 853-859, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32681688

RESUMO

BACKGROUND: Intralesional vitamin D3 has recently emerged as a new treatment for cutaneous warts. The use of the measles, mumps, and rubella (MMR) vaccine for this purpose is an established modality. However, relevant data on the efficacy of either the MMR vaccine or vitamin D3 as immunotherapy for cutaneous warts in the pediatric population are limited. OBJECTIVES: To compare the efficacy and safety of intralesional injections of MMR vaccine to intralesional injections of vitamin D3 in children aged 8-16 years with multiple warts. METHODS: A total of 74 children were randomly allocated into two groups. Group A patients received intralesional MMR vaccine into the largest wart, and group B received intralesional vitamin D3 into the largest wart. The injections were repeated every 4 weeks until clearance or for a maximum of three treatments. After the last injection, children were followed up every 2 weeks for 3 months, and at the sixth month, a final clinical assessment was conducted. RESULTS: Of 74 children, 60 completed the study, with 30 children in each group. Complete clearance of the injected wart was observed in 26 (86.67%) patients in the MMR group (group A) and 23 (76.7%) patients in the vitamin D3 group (group B). Distant warts cleared in 23 (76.7%) patients in group A compared to 20 (66.6%) patients in group B. There was no significant difference between groups. No recurrence was seen in group A, whereas two (6.6%) children in group B exhibited recurrence in the ensuing 6-month follow-up. The most common adverse events were injection site pain and swelling. CONCLUSION: Both intralesional MMR and vitamin D3 are safe, generally well-tolerated, and equally effective in children for the treatment of cutaneous warts.


Assuntos
Sarampo , Caxumba , Vacinas , Verrugas , Adolescente , Criança , Colecalciferol/uso terapêutico , Humanos , Injeções Intralesionais , Vacina contra Sarampo-Caxumba-Rubéola/efeitos adversos , Recidiva Local de Neoplasia , Vacina contra Rubéola/uso terapêutico , Vacinas/uso terapêutico , Verrugas/tratamento farmacológico
4.
Vaccimonitor (La Habana, Print) ; 28(1)ene.-abr. 2019. tab, graf
Artigo em Espanhol | LILACS, CUMED | ID: biblio-1094618

RESUMO

En las meningoencefalitis de etiología viral se encuentran implicados los paramixovirus (virus de la parotiditis, sarampión y rubeola). Las vacunas combinadas trivalentes han sido utilizadas durante años en muchos países. El objetivo del trabajo es determinar la respuesta poliespecífica de anticuerpos de tipo IgG anti parotiditis, rubeola y sarampión en pacientes pediátricos con meningoencefalitis víricas agudas. Se realizó un estudio retrospectivo en el año 2018 en muestras de pacientes pediátricos con meningoencefalitis viral aguda vacunados con la triple viral, donde se utilizó el índice de anticuerpos específicos anti-parotiditis, anti-rubeola y anti-sarampión para identificar el estado de respuesta inmunológica contra dichos virus en la muestra estudiada, procedentes de la serorraquioteca de LABCEL. Las determinaciones se hicieron por ELISA. Todos los pacientes presentaron respuesta poliespecífica intratecal, disminución significativa del índice de anticuerpos IgG anti-parotiditis con respecto a la edad y al tiempo de respuesta. Se evidencia un acortamiento del tiempo de respuesta de los anticuerpos de tipo IgG específicos anti-parotiditis en relación a la edad de vacunación(AU)


Paramixovirus like mumps, rubella and measles are involved in some viral meningoencephalitis. Triple combined vaccines have been employed for several years in many countries. The aim of this work is to determine the IgG anti mumps, rubella and measles polyspecific response in pediatric patients with acute viral meningoencephalitis. A 2018 retrospective study in pediatric patients with acute viral meningoencephalitis previously vaccinated with the triple viral vaccine MMR was performed to identify the immune response status against mumps, rubella and measles in samples from LABCEL serum and cerebrospinal fluid collection. Quantification of IgG specific antibody was performed by ELISA. Intrathecal polyspecific response was present in all patients. A significant decrement of anti IgG mumps specific antibody index was observed according to age and response time. A shortage of the response time of IgG mumps specific antibodies according to the age of vaccination was demonstrated(AU)


Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Parotidite/prevenção & controle , Vacina contra Rubéola/uso terapêutico , Vacinas/uso terapêutico , Sarampo/prevenção & controle , Meningoencefalite/etiologia , Estudos Retrospectivos , Cuba
7.
Res Dev Disabil ; 35(11): 3182-90, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25151608

RESUMO

Childhood hearing impairment (CHI) is a major developmental disability, but data at the national level are limited, especially those on the changes in the prevalence over time. In Taiwan, the government began to certify disabled residents for providing various services in 1980 and maintains a registry of certified cases, which provides a rare opportunity for studying the trends of CHI prevalence. Using the registry data, we estimated the prevalence of CHI by age and severity and explored factors affecting its changes over time. From 2000 to 2011, the registered cases under 17 years old ranged from 3427 to 4075. The overall prevalence increased from 2000 to 2006, but then decreased till 2011. While the prevalence of mild CHI increased over the years, such a pattern was not observed in moderate or severe CHI. In general, the overall prevalence increased over the years in the age groups <3 years, 3-5 years, and 6-11 years (p<0.01), and the largest increase was observed in the age group <3 years, particularly after the promotion of screening by the government in 2003. The decrease after 2006 was mainly attributable to decreases in the age groups 12-14 (with a decreasing trend from 2001, p<0.01) and 15-17 years (with a decreasing trend from 2004, p<0.01). The timing was related to the implementation of a nationwide rubella vaccination program. Similar decreases had been observed in countries with rubella vaccination programs.


Assuntos
Perda Auditiva/epidemiologia , Programas de Imunização , Sistema de Registros , Síndrome da Rubéola Congênita/prevenção & controle , Vacina contra Rubéola/uso terapêutico , Adolescente , Criança , Pré-Escolar , Perda Auditiva/etiologia , Perda Auditiva/prevenção & controle , Humanos , Lactente , Recém-Nascido , Programas de Rastreamento , Prevalência , Síndrome da Rubéola Congênita/complicações , Índice de Gravidade de Doença , Taiwan/epidemiologia
8.
Eur J Public Health ; 18(6): 688-90, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18927183

RESUMO

In this short report we highlight the importance of implementing good immunization programs adapted to the epidemiological situation of rubella and congenital rubella syndrome (CRS), discuss the influence of massive immigration and stress the need to improve surveillance and control by implementing comprehensive national surveillance and promoting awareness among primary healthcare workers and midwives to find out any signs and symptoms compatible with rubella in pregnant women who have recently arrived from countries with high susceptibility to rubella infection.


Assuntos
Emigração e Imigração/estatística & dados numéricos , Síndrome da Rubéola Congênita/epidemiologia , Síndrome da Rubéola Congênita/prevenção & controle , Vacina contra Rubéola/uso terapêutico , Surtos de Doenças , Humanos , Programas de Rastreamento , Vigilância de Evento Sentinela , Espanha/epidemiologia
9.
J Pediatr Hematol Oncol ; 27(5): 273-7, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15891564

RESUMO

The objective of this study was to investigate the diphtheria-tetanus-pertussis and/or measles-mumps antibody titers before and after vaccination at various time points of acute lymphoblastic leukemia (ALL) therapy and to suggest an appropriate vaccination approach for ALL patients. The authors studied 37 ALL patients and 14 healthy control subjects, divided into three groups. In group 1 (newly diagnosed patients), baseline anti-diphtheria, anti-tetanus, and anti-pertussis titers were determined. Patients in group 2 (on maintenance chemotherapy) and group 3 (patients not receiving therapy for 3-6 months) were vaccinated with diphtheria-tetanus with or without acellular pertussis; group 3 and control subjects were also given measles-mumps-rubella vaccine. Preimmunization and 1-month postimmunization titers were drawn. Preimmunization anti-diphtheria and anti-tetanus antibody titers between the groups and the controls were statistically similar. The seropositivity rate for anti-measles antibody in group 3 was significantly lower than controls. After vaccination, all of the patients developed protective anti-diphtheria and anti-tetanus antibody titers. The seroconversion rates of group 3 and controls for anti-measles and anti-mumps antibodies were statistically similar. The results showed that patients on maintenance therapy and after cessation of therapy made good antibody responses to diphtheria and tetanus toxoids, but response to measles and mumps vaccines was not as sufficient as toxoid vaccines. Children with ALL can receive the appropriate vaccines during and after maintenance treatment.


Assuntos
Formação de Anticorpos , Vacina contra Difteria, Tétano e Coqueluche/uso terapêutico , Vacina contra Sarampo/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/imunologia , Vacina contra Rubéola/uso terapêutico , Adolescente , Antineoplásicos/uso terapêutico , Criança , Pré-Escolar , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Humanos , Imunização/métodos , Vacina contra Sarampo/imunologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Valores de Referência , Vacina contra Rubéola/imunologia
11.
Clin Diagn Lab Immunol ; 7(6): 964-6, 2000 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11063507

RESUMO

The protective immune responses against rubella virus (RV) are related to its neutralizing epitopes, an issue that is important to consider when assessing the immune status of patients with remote infection. In the present paper, we compare the antibodies detected by a synthetic-peptide-based enzyme immunoassay (EIA) with antibodies detected by the traditional technique of hemagglutination inhibition (HIA) in patients with remote RV infection. The synthetic peptide used as an antigen (SP15) represents a neutralizing epitope that corresponds to amino acids 208 to 239 of the E1 glycoprotein. The SP15-EIA was developed, all variables that affected the assay were standardized, and the test was validated using reference sera. Serum samples (n = 129) from patients with remote RV infection were tested by HIA and SP15-EIA. Discrepant sera were assayed by MEIA (IMX/Abbot). The comparison between HIA and SP15-EIA, taking HIA as the standard methodology for determining immune status, showed that SP15-EIA is very specific and sensitive for detecting protecting antibodies (specificity, 100%; sensitivity, 98.20%). This study demonstrates that antibodies against the neutralizing domain represented by SP15 would be important in the memory response after natural infection and may be a good tool in the determination of the true immune status of patients with remote infection with regard to RV.


Assuntos
Anticorpos Antivirais , Vírus da Rubéola/imunologia , Adulto , Epitopos , Feminino , Testes de Inibição da Hemaglutinação , Humanos , Técnicas Imunoenzimáticas , Testes de Neutralização , Estrutura Terciária de Proteína , Rubéola (Sarampo Alemão)/imunologia , Rubéola (Sarampo Alemão)/prevenção & controle , Vacina contra Rubéola/uso terapêutico , Proteínas do Envelope Viral
12.
Vaccine ; 18(14): 1393-401, 2000 Jan 31.
Artigo em Inglês | MEDLINE | ID: mdl-10618537

RESUMO

The correlates of long-term protection from measles infection are poorly understood. We followed the development of measles-specific antibody and lymphoproliferative (LP) responses in 60 children for 6 months after MMR vaccination. Prevaccine plaque reduction neutralization antibody (PRN Ab) values were low (mean+/-SEM 9.9+/-1. 1). Ninety-three percent (56/60) had excellent PRN values at 6 months (PRN 1816+/-207). Prevaccine LP activity was also low (stimulation index (SI)=1.4+/-0.1) but increased rapidly (SI 10. 7+/-4.5 at 2-3 weeks; p<0.05). However, only 61% (37/60) of the children had both significant cellular and antibody responses (SI>/=3 and PRN>/=120: Ab(hi)CMI(hi)). One child had a strong LP response (SI=6.7) despite little antibody production (PRN=19 at 6 months: Ab(lo)CMI(hi)). We also conducted a cross-sectional study in a separate group of 87 children 5-13 years after MMR vaccination. PRN values >/=120 were present in most children at 5-8 (n=28) and 9-13 years (n=59) after vaccination (PRN 550+/-120 and 360+/-60, respectively) but a significant minority had either undetected or 'subprotective' values (29 and 34%, respectively). LP responses (SI>/=3) were detectable in 19/28 (66%) and 36/59 (56%) of the children 5-8 and 9-13 years after vaccination (SI 11.4+/-2.4 and 7. 75+/-1.9, respectively). Almost two thirds (18/28) of the children in the cross-sectional study with low or absent antibody titers (PRN 41+/-6) had strong LP responses to measles antigens (SI 6.8+/-1.3). These data suggest that LP responses may be better sustained than antibody titers in some children. The susceptibility of Ab(lo)CMI(hi) children to infection and the value of the early LP response for predicting the durability of immunity remain to be determined.


Assuntos
Antígenos Virais/imunologia , Ativação Linfocitária , Vacina contra Sarampo/imunologia , Vírus do Sarampo/imunologia , Vacina contra Caxumba/imunologia , Vacina contra Rubéola/imunologia , Adolescente , Anticorpos/imunologia , Formação de Anticorpos , Criança , Pré-Escolar , Feminino , Humanos , Imunidade Celular , Lactente , Masculino , Vacina contra Sarampo/uso terapêutico , Vacina contra Sarampo-Caxumba-Rubéola , Vacina contra Caxumba/uso terapêutico , Estudos Prospectivos , Vacina contra Rubéola/uso terapêutico , Vacinação , Vacinas Combinadas/imunologia , Vacinas Combinadas/uso terapêutico
13.
Pediatr. día ; 15(4): 235-43, sept.-oct. 1999. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-258153

RESUMO

En los últimos años se ha observado un cambio en la situación epidemiológica de la rubéola en nuestro país. Hasta la introducción de la vacuna en 1990, la rubéola afectaba básicamente a los niños menores de 10 años. A partir de esta fecha su incidencia fue descendiendo considerablemente, pero en 1997 se observó un repunte en distintas regiones del país; la diferencia es que ahora la enfermedad estaba afectando a adolescentes y adultos jóvenes, existiendo por tanto el riesgo de que nacieran niños con síndrome de rubéola congénita. La respuesta era inevitable, había que vacunar


Assuntos
Humanos , Recém-Nascido , Programas de Imunização , Síndrome da Rubéola Congênita/prevenção & controle , Chile/epidemiologia , Imunoglobulina M , Síndrome da Rubéola Congênita/diagnóstico , Síndrome da Rubéola Congênita/epidemiologia , Síndrome da Rubéola Congênita/fisiopatologia , Sinais e Sintomas , Vacina contra Rubéola/uso terapêutico
14.
Br J Cancer ; 81(1): 175-8, 1999 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10487630

RESUMO

Previous studies have suggested that infant vaccinations may reduce the risk of subsequent childhood leukaemia. Vaccination histories were compared in 439 children (ages 0-14) diagnosed with acute lymphoblastic leukaemia (ALL) in nine Midwestern and Mid-Atlantic states (USA) between 1 January 1989 and 30 June 1993 and 439 controls selected by random-digit dialing and individually matched to cases on age, race and telephone exchange. Among matched pairs, similar proportions of cases and controls had received at least one dose of oral poliovirus (98%), diphtheria-tetanus-pertussis (97%), and measles-mumps-rubella (90%) vaccines. Only 47% of cases and 53% of controls had received any Haemophilus influenzae type b (Hib) vaccine (relative risk (RR) = 0.73; 95% confidence interval (CI) 0.50-1.06). Although similar proportions of cases (12%) and controls (11%) received the polysaccharide Hib vaccine (RR = 1.13; 95% CI 0.64-1.98), more controls (41%) than cases (35%) received the conjugate Hib vaccine (RR = 0.57; 95% CI 0.36-0.89). Although we found no relationship between most infant vaccinations and subsequent risk of childhood ALL, our findings suggest that infants receiving the conjugate Hib vaccine may be at reduced risk of subsequent childhood acute lymphoblastic leukemia. Further studies are needed to confirm this association and, if confirmed, to elucidate the underlying mechanism.


Assuntos
Esquemas de Imunização , Vacina contra Sarampo-Caxumba-Rubéola , Leucemia-Linfoma Linfoblástico de Células Precursoras/epidemiologia , Adolescente , Cápsulas Bacterianas , Vacina contra Varicela , Criança , Pré-Escolar , Vacina contra Difteria, Tétano e Coqueluche/efeitos adversos , Vacina contra Difteria, Tétano e Coqueluche/uso terapêutico , Feminino , Vacinas Anti-Haemophilus/efeitos adversos , Vacinas Anti-Haemophilus/uso terapêutico , Humanos , Lactente , Recém-Nascido , Masculino , Vacina contra Sarampo/efeitos adversos , Vacina contra Sarampo/uso terapêutico , Vacina contra Caxumba/efeitos adversos , Vacina contra Caxumba/uso terapêutico , Polissacarídeos Bacterianos/efeitos adversos , Polissacarídeos Bacterianos/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/etiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevenção & controle , Fatores de Risco , Vacina contra Rubéola/efeitos adversos , Vacina contra Rubéola/uso terapêutico , Estados Unidos/epidemiologia , Vacinas Combinadas/efeitos adversos , Vacinas Combinadas/uso terapêutico , Vacinas Virais/efeitos adversos , Vacinas Virais/uso terapêutico
18.
Aust J Public Health ; 17(3): 231-6, 1993 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8286496

RESUMO

An outbreak of measles occurred in Darwin from February to March 1991. The first case was in a 13-year-old high school student who had returned from a holiday overseas. She was symptomatic on the second day of the new school term. She infected an infant while both waited in a doctor's surgery. Outbreak control measures were instituted 18 days later when the Communicable Diseases Centre was first alerted of cases through the laboratory notification scheme. Through active surveillance, we identified 76 cases of measles, of whom 92 per cent (70 cases) were under 20 years of age. Of these, 46 were students at the index high school in which the attack rate was 39.2 per 1,000. They transmitted the disease to six unvaccinated siblings aged 11 to 18 years, resulting in a secondary attack rate of 113 per 1,000 in this age group (relative risk of disease in siblings 2.8, 95 per cent confidence interval 1.2 to 6.2). The outbreak affected one other high school, a number of primary schools, one tertiary institution, and nine children under five years. Only four of the cases had a verified history of previous immunisation against measles. The outbreak was arrested within two weeks of instituting community-wide control measures. Inadequate immunisation coverage among school-aged children and delays in notification contributed to the severity of the outbreak. Improved measles surveillance systems, including telephone notification of clinical cases are needed so that control measures can be instituted immediately within the household and in the community.


Assuntos
Surtos de Doenças/prevenção & controle , Sarampo/epidemiologia , Adolescente , Adulto , Criança , Pré-Escolar , Combinação de Medicamentos , Humanos , Lactente , Sarampo/prevenção & controle , Vacina contra Sarampo/uso terapêutico , Vacina contra Sarampo-Caxumba-Rubéola , Pessoa de Meia-Idade , Vacina contra Caxumba/uso terapêutico , Northern Territory/epidemiologia , Vigilância da População , Vacina contra Rubéola/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA